Peptide 101: BPC-157 (Body Protection Compound-157)

BPC-157 is a peptide derived from a stomach protein that shows dramatic healing effects in animal studies — accelerating recovery of tendons, muscles, gut, and nerves. The preclinical evidence is extensive and consistent, which is why it has gained a large following in athletic and recovery communities. However, human clinical trials have not been completed, so we do not yet know if these effects translate to people, what the right dose is, or what the long-term risks are.

If tissue healing is like rebuilding a city after a disaster, BPC-157 acts like an emergency dispatcher that simultaneously calls in the construction crews (fibroblasts), turns on the water supply (angiogenesis), calms the fires (inflammation), and clears the roads so supply trucks can get through — all at the same time.

BPC-157 promotes angiogenesis through upregulation of VEGF and VEGFR2, accelerating formation of new blood vessels into injured tissue. It activates FAK (focal adhesion kinase) and paxillin signaling pathways in fibroblasts and myocytes, promoting cell migration and tissue repair. It modulates nitric oxide (NO) synthesis, supports growth hormone receptor expression in injured tissue, and exerts gastroprotective effects by maintaining mucosal integrity and cytoprotective prostaglandin pathways. Inflammation-modulating effects involve NF-κB suppression.

Overall strength of the evidence, by our read: Emerging. Some of what that rests on:

Preliminary or early findings are not the same as proof. Any use beyond a peptide's FDA-approved labeling (where one exists) is described here for educational purposes only and is not a recommendation.

No significant adverse effects have been identified in animal studies even at very high doses. Human case series and anecdotal reports describe good tolerability. Theoretical concerns include pro-angiogenic effects potentially stimulating tumor vasculature. No long-term human safety data exists.

Reasons to avoid it, or to talk to a clinician first:

This is not a complete safety list, and none of it is dosing advice.

Topics we'll be tracking:

Peptide Disclaimer: BPC-157 has NOT been approved by the U.S. Food and Drug Administration for any medical use. As of 2023-09-29, the FDA placed this substance on the Category 2 list of bulk drug substances under Section 503A of the FD&C Act, meaning compounding pharmacies are prohibited from compounding it under the FDA's interim policy. Research discussed below may include preclinical, animal, or preliminary studies that do not establish safety or efficacy in humans. Compounded versions of BPC-157 are NOT the same as FDA-approved products. Compounded drugs have not undergone FDA review for safety, efficacy, or manufacturing quality. The FDA has warned that compounded versions may contain different salt forms, concentrations, or impurities. Discuss the risks and regulatory status of compounded medications with your prescriber. IMPORTANT: The available research on BPC-157 consists primarily of preclinical studies (animal models and/or in vitro experiments). These results may not translate to humans. No controlled human clinical trials have established the safety or efficacy of this substance for any indication. NOTE: A policy announcement regarding potential reclassification of this substance was made in February 2026. However, as of the date of this content, no formal FDA rule change has been published in the Federal Register. The current regulatory status described above remains in effect until a formal rule is finalized.

Medical Disclaimer: This newsletter is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. No provider-patient relationship is created by reading this newsletter. Always consult your healthcare provider before making health decisions.